BindingDB logo
myBDB logout

66 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
27876250 60 Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CHEBI Jagiellonian University Medical College
25905598 59 Rational design of dual peptides targeting ghrelin and Y2 receptors to regulate food intake and body weight.EBI Universit£t Leipzig
24365162 126 Ligands of the neuropeptide Y Y2 receptor.EBI The Scripps Research Institute
24900634 36 Design and Synthesis of Peptide YY Analogues with C-terminal Backbone Amide-to-Ester Modifications.EBI University of Copenhagen
24074877 135 Dimeric argininamide-type neuropeptide Y receptor antagonists: chiral discrimination between Y1 and Y4 receptors.EBI University of Regensburg
24090364 96 Replacement of Thr32 and Gln34 in the C-terminal neuropeptide Y fragment 25-36 by cis-cyclobutane and cis-cyclopentane β-amino acids shifts selectivity toward the Y(4) receptor.EBI University of Regensburg
23756063 25 The discovery of potent selective NPY Y(2) antagonists.EBI Janssen Research& Development LLC
23582449 20 Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor.EBI Institute of Organic Synthesis
23466604 36 Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds.EBI Universit£ degli Studi di Siena
23403082 28 Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.EBI Broad Institute of MIT and Harvard
23176753 5 Cyclic analogs of galanin and neuropeptide Y by hydrocarbon stapling.EBI University of Utah
21074426 34 The identification of a series of novel, soluble non-peptidic neuropeptide Y Y2 receptor antagonists.EBI GlaxoSmithKline
22607676 47 Synthesis and SAR of selective small molecule neuropeptide Y Y2 receptor antagonists.EBI The Scripps Research Institute
20931963 112 Discovery of a novel 5-HT(3) antagonist/5-HT(1A) agonist 3-amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-yl)piperazin-1-yl]butyl}quinazolin-4(3H)-one (TZB-30878) as an orally bioavailable agent for irritable bowel syndrome.EBI ASKA Pharmaceutical Co, Ltd
18160282 40 Discovery of novel orally active ureido NPY Y5 receptor antagonists.EBI Schering-Plough Research Institute
1433176 26 Truncated, branched, and/or cyclic analogues of neuropeptide Y: importance of the pancreatic peptide fold in the design of specific Y2 receptor ligands.EBI Salk Institute
21782428 61 Discovery of Lu AA33810: a highly selective and potent NPY5 antagonist with in vivo efficacy in a model of mood disorder.EBI Lundbeck Research USA, Inc.
21802951 29 The discovery and synthesis of JNJ 31020028, a small molecule antagonist of the Neuropeptide Y Y2 receptor.EBI Johnson& Johnson Pharmaceutical Research& Development
19616955 34 Discovery of pyridone-containing imidazolines as potent and selective inhibitors of neuropeptide Y Y5 receptor.EBI Tsukuba Research Institute
21493077 39 Red-fluorescent argininamide-type NPY Y1 receptor antagonists as pharmacological tools.EBI Universit£t Regensburg
21295475 21 Discovery and evaluation of pyrazolo[1,5-a]pyrimidines as neuropeptide Y1 receptor antagonists.EBI Pfizer Inc.
20813948 63 Spiroindolones, a potent compound class for the treatment of malaria.EBI Swiss Tropical and Public Health Institute
20630754 33 Synthesis and structure-activity relationship of N-(3-azabicyclo[3.1.0]hex-6-ylmethyl)-5-(2-pyridinyl)-1,3-thiazol-2-amines derivatives as NPY Y5 antagonists.EBI GlaxoSmithKline
20591666 66 A new group of oxime carbamates as reversible inhibitors of fatty acid amide hydrolase.EBI Università degli Studi di Milano
19864135 43 Discovery and SAR of cyclic isothioureas as novel NPY Y1 receptor antagonists.EBI Schering Plough Research Institute
20042335 12 [Lys(DOTA)4]BVD15, a novel and potent neuropeptide Y analog designed for Y1 receptor-targeted breast tumor imaging.EBI Universit£ de Sherbrooke
19679469 26 Identification of positron emission tomography ligands for NPY Y5 receptors in the brain.EBI Tsukuba Research Institute
19640706 25 Synthesis and evaluation of a series of 2,4-diaminopyridine derivatives as potential positron emission tomography tracers for neuropeptide Y Y1 receptors.EBI Tsukuba Research Institute
19596193 72 Design, synthesis and evaluation of a novel cyclohexanamine class of neuropeptide Y Y1 receptor antagonists.EBI Tsukuba Research Institute
19581086 37 The identification and optimisation of novel and selective diamide neuropeptide Y Y2 receptor antagonists.EBI GlaxoSmithKline
 13 Novel Y2-selective, reduced-size agonists of neuropeptide YEBI TBA
19464889 43 Aryl urea derivatives of spiropiperidines as NPY Y5 receptor antagonists.EBI Tsukuba Research Institute
19459652 56 Discovery of tetrasubstituted imidazolines as potent and selective neuropeptide Y Y5 receptor antagonists: reduced human ether-a-go-go related gene potassium channel binding affinity and potent antiobesity effect.EBI Tsukuba Research Institute
19053784 19 Guanidine-acylguanidine bioisosteric approach in the design of radioligands: synthesis of a tritium-labeled N(G)-propionylargininamide ([3H]-UR-MK114) as a highly potent and selective neuropeptide Y Y1 receptor antagonist.EBI University of Regensburg
18752943 36 Syntheses and structure-activity relationships of novel, potent, and selective trans-2-[3-oxospiro[isobenzofuran-1(3H),1'-cyclohexan]-4'-yl]benzimidazole NPY Y5 receptor antagonists.EBI Banyu Tsukuba Research Institute
18723347 59 Design, syntheses, and structure-activity relationships of novel NPY Y5 receptor antagonists: 2-{3-Oxospiro[isobenzofuran-1(3H),4'-piperidin]-1'-yl}benzimidazole derivatives.EBI Banyu Tsukuba Research Institute
18637668 38 (9S)-9-(2-hydroxy-4,4-dimethyl-6-oxo-1-cyclohexen-1-yl)-3,3-dimethyl-2,3,4,9-tetrahydro-1H-xanthen-1-one, a selective and orally active neuropeptide Y Y5 receptor antagonist.EBI Tsukuba Research Institute
17425299 8 Novel selective neuropeptide Y2 receptor PEGylated peptide agonists reduce food intake and body weight in mice.EBI Bayer Pharmaceuticals Corporation
17292607 12 A long-acting selective neuropeptide Y2 receptor PEGylated peptide agonist reduces food intake in mice.EBI Bayer Pharmaceuticals Corporation
17055726 68 Identification of selective neuropeptide Y2 peptide agonists.EBI Bayer Pharmaceuticals Corporation
16610810 39 Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar affinity.EBI University of Cincinnati
15109631 86 Discovery and SAR of potent, orally available and brain-penetrable 5,6-dihydro-4H-3-thia-1-aza-benzo[e]azulen- and 4,5-dihydro-6-oxa-3-thia-1-aza-benzo[e]azulen derivatives as neuropeptide Y Y5 receptor antagonists.EBI Novartis Pharma AG
14980673 54 Novel non-peptidic neuropeptide Y Y2 receptor antagonists.EBI Johnson & Johnson Pharmaceutical Research and Development
14611849 16 Differentially functionalized diamines as novel ligands for the NPY2 receptor.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
11428928 70 Synthesis and structure-activity relationships of trisubstituted phenyl urea derivatives as neuropeptide Y5 receptor antagonists.EBI Amgen Inc.
11334558 42 Highly selective and potent neuropeptide Y (NPY) Y1 receptor antagonists based on [Pro(30), Tyr(32), Leu(34)]NPY(28-36)-NH2 (BW1911U90).EBI University of Cincinnati and VA Medical Centers
10978189 115 Structure-activity studies including a Psi(CH(2)-NH) scan of peptide YY (PYY) active site, PYY(22-36), for interaction with rat intestinal PYY receptors: development of analogues with potent in vivo activity in the intestine.EBI University of Cincinnati Medical Center
10915060 54 Structure-activity relationships of neuropeptide Y Y1 receptor antagonists related to BIBP 3226.EBI University of Regensburg
10866375 50 Design, synthesis and SAR of a series of 2-substituted 4-amino-quinazoline neuropeptide Y Y5 receptor antagonists.EBI Novartis Pharma AG
9371234 49 Potent and selective 1,2,3-trisubstituted indole NPY Y-1 antagonists.EBI Lilly Research Laboratories
8632403 14 Bis(31/31') ([CYS(31), Trp(32), Nva(34)] NPY-(31-36)): a specific NPY Y-1 receptor antagonist.EBI University of Cincinnati Medical Center
8426366 44 Defining structural requirements for neuropeptide Y receptors using truncated and conformationally restricted analogues.EBI Salk Institute
8254609 61 Neuropeptide Y: Y1 and Y2 affinities of the complete series of analogues with single D-residue substitutions.EBI Salk Institute
16436501 8 Pharmacological characterization and feeding-suppressive property of FMS586 [3-(5,6,7,8-tetrahydro-9-isopropyl-carbazol-3-yl)-1-methyl-1-(2-pyridin-4-yl-ethyl)-urea hydrochloride], a novel, selective, and orally active antagonist for neuropeptide Y Y5 receptor.BDB Meiji Seika Kaisha, Ltd.
15131245 86 SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization.BDB Sanofi-Synthelabo Recherche
11502885 35 Identification of potent and selective neuropeptide Y Y(1) receptor agonists with orexigenic activity in vivo.BDB Schering-Plough Research Institute
10944518 27 The first selective agonist for the neuropeptide YY5 receptor increases food intake in rats.BDB Federal Institute of Technology of Zurich
9454810 72 SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.BDB Sanofi Recherche
7796807 51 The 5-HT4 receptor: molecular cloning and pharmacological characterization of two splice variants.BDB Synaptic Pharmaceutical Corporation
7592910 36 Expression cloning and pharmacological characterization of a human hippocampal neuropeptide Y/peptide YY Y2 receptor subtype.BDB Synaptic Pharmaceutical Corporation
7559383 11 Cloning and functional expression of a cDNA encoding a human type 2 neuropeptide Y receptor.BDB Bristol Myers Squibb